Vaxcyte (PCVX) Operating Leases (2021 - 2026)

Vaxcyte (PCVX) has 6 years of Operating Leases data on file, last reported at $110.2 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $110.2 million, up 35.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $110.2 million (up 35.93% YoY), and the FY2025 annual result was $111.5 million, up 70.9% from the prior year.
• Operating Leases retreated to $110.2 million in Q1 2026 per PCVX's latest filing, from $111.5 million in the prior quarter.
• Over five years, Operating Leases peaked at $111.5 million in Q4 2025 and troughed at $7.8 million in Q3 2023.
• A 5-year average of $41.4 million and a median of $20.2 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases jumped 6371.11% in 2022, then plunged 41.74% in 2023.
• A 5-year view of Operating Leases shows it stood at $12.9 million in 2022, then surged by 71.4% to $22.1 million in 2023, then soared by 194.96% to $65.2 million in 2024, then soared by 70.9% to $111.5 million in 2025, then retreated by 1.12% to $110.2 million in 2026.
• Business Quant data shows PCVX's Operating Leases at $110.2 million in Q1 2026, $111.5 million in Q4 2025, and $78.7 million in Q3 2025.